about
Melanoma-associated antigen synthesized in vitro for active specific immunotherapy.Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient.Class 1 (unique) tumor antigens of human melanoma: identification of unique and common epitopes on a 90-kDa glycoprotein.Recognition of galactosylgloboside by monoclonal antibodies derived from patients with primary lung cancerClinical implications of the new biology in the development of melanoma vaccines.Human IgM antibody therapy for HIV-1 infection.Natural and induced human antibody response to cancer.Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody.Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes.Cell-surface antigens of melanoma recognized by human monoclonal antibodiesVaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.Isolation and partial characterization of melanoma-associated antigens identified by autologous antibody.Cellular immuno-PCR. Detection of a carbohydrate tumor marker.Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteinsEpitope- and antigen-specific cancer vaccines.Role of gangliosides in active immunotherapy with melanoma vaccine.Application of carbohydrate array technology to antigen discovery and vaccine development.Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies.Simple sugars to complex disease--mucin-type O-glycans in cancer.A multicolor nanoprobe for detection and imaging of tumor-related mRNAs in living cells.Tumor antigens known to be immunogenic in man.Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer.Update on active specific immunotherapy with melanoma vaccines.Alloimmunization with cultured human stomach cancer cell lines and the establishment of human-human hybridomas producing monoclonal antibodies.The CLIMB (Complex Lipids In Mothers and Babies) study: protocol for a multicentre, three-group, parallel randomised controlled trial to investigate the effect of supplementation of complex lipids in pregnancy, on maternal ganglioside status and subPolyvalent melanoma vaccine improves survival of patients with metastatic melanoma.A monoclonal antibody reacting specifically with ganglioside GD1b in human brain.Induction of mouse anti-melanoma cytotoxic and suppressor T cells in vitro by an artificial antigen, GM3-lactone.Density of GM3 with normal primary structure determines mouse melanoma antigenicity; a new concept of tumor antigen.A human monoclonal antibody recognizing a surface antigen on stomach cancer cells.
P2860
Q33188234-B81A866B-F109-4EC2-8D18-BAF2B24863F8Q33557110-45977CAC-C2B8-4515-B628-3EC3A57A3CF2Q33578451-9D800849-4C0F-4CB6-801D-87EE9A7E24A2Q33582426-5B287F0E-3898-48EB-AE1A-11DB0999C3A1Q33603062-C66B7505-A1C3-485C-B73A-716EE3A159DDQ33753260-467EC0E3-29B2-42E7-8155-AAA2532163CCQ33931150-12405B1F-8131-4757-8D2A-018FD255EC5AQ34225498-FC662E09-5475-4D56-A87A-16FBECB82C15Q34504625-79E2AC04-3A40-4769-A517-5D74DEF75D96Q34550480-8E13AC90-0681-49D5-9FA0-F7B9A06191B6Q34614430-44987209-9611-48EF-AE3C-7ACB95B69612Q34619348-281B0814-7FFA-4C00-ADD6-38A0278711D4Q35589402-39378CA9-C8D3-4621-984A-8809A4C58A95Q35765166-54683EA7-73C9-459A-A822-4FFF7F1EBA6FQ36214624-CB0D49DF-4A26-43B9-AE69-2ECC55855BBEQ36930069-2E2C0799-9AF2-41E2-BF3B-32162A36BD1CQ36930077-545536FA-F5B7-4DE2-8B38-71C12FA66C99Q37123455-FC726F60-795F-4EBB-B1C6-708413CB869FQ37407762-63A67C9C-6CF2-479B-816E-5D174E4C312CQ37952804-BF1AFDE6-B0CE-441A-8BFE-6B1EFC611584Q38195895-D6CC7631-F2EB-423D-BDEE-11A34B830FA8Q38366325-3C9E561B-A217-45A8-85B9-E6C788B1BD81Q39312879-A4B2FB29-4467-4562-83BA-C56D095B059CQ40844527-922C4A41-705F-4DA2-BC08-1C956224A7E2Q41014965-153F6E44-1807-4F41-B7DA-AA5B6A475829Q41589321-267D8C43-79C3-427E-9260-D054BDC1802CQ41720203-752D020D-0957-4E93-8F33-AF2AC6971BF7Q42650088-6D7A1C4C-BED0-43B2-ABC7-0AAB0AE5858FQ46127721-6FC46CBA-DF31-46D5-86A8-56EE4DB32917Q48453595-70A3FE4A-480E-44D5-915A-04F8E86EDA9EQ54953576-58F49C00-0EC7-4FB1-A507-FD8F2D879F29Q55036688-3F5C5634-B0D2-4CE2-8937-941B9FE22651Q55317230-BEFBB73D-1969-4671-8BDC-C74C3097DAD1
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 1983
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ganglioside GM2 as a human tumor antigen (OFA-I-1).
@en
Ganglioside GM2 as a human tumor antigen
@nl
type
label
Ganglioside GM2 as a human tumor antigen (OFA-I-1).
@en
Ganglioside GM2 as a human tumor antigen
@nl
prefLabel
Ganglioside GM2 as a human tumor antigen (OFA-I-1).
@en
Ganglioside GM2 as a human tumor antigen
@nl
P2093
P2860
P356
P1476
Ganglioside GM2 as a human tumor antigen (OFA-I-1).
@en
P2093
P2860
P304
P356
10.1073/PNAS.80.17.5392
P407
P577
1983-09-01T00:00:00Z